SAN
DIEGO, April 5, 2022 /PRNewswire/
-- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with
four clinical programs in development and an emerging pre-clinical
pipeline, announced today that late-breaking data from INBRX-101
will be presented at the American Thoracic Society ("ATS") 2022
Conference to be held May
13th- 18th, 2022 in San Francisco, CA.
Details on the oral presentation are shared below:
Title: INBRX-101: A Novel Recombinant AAT-Fc Fusion
Protein That Achieves Normal Serum AAT Levels with Extended
Interval Dosing for Patients with Alpha-1 Antitrypsin
Deficiency
Session: Late Breaking Mini Symposium. B14.
OLD DOGS NEW TRICKS: LATE-BREAKING ABSTRACTS IN OBSTRUCTIVE LUNG
DISEASE
Senior Author: Mark
Brantly
Date & Time: May 16, 2022, 10:30-10:40
AM PST
Location: Room 3001/3003 (West Building,
Level 3), Moscone Center
Details on the poster presentation are shared below:
Title: Evaluation of Safety and Pharmacokinetics of the
Recombinant Human AAT-Fc Fusion Protein INBRX-101 in Patients with
Alpha-1 Antitrypsin Deficiency
Poster Session: C41.
ALPHA-1 ANTITRYPSIN DEFICIENCY
Poster: P393
Lead Speaker: Andrew
Veale
Date & Time: May
17, 2022, 11:15 AM - 1:15 PM
PST
Location: Area E, Hall F (North Building,
Exhibition Level), Moscone Center
Upon release at ATS, the poster and presentation will be
accessible through Inhibrx's website at
https://inhibrx.investorroom.com/events-and-presentations.
About AATD and INBRX-101
Alpha-1 Antitrypsin Deficiency ("AATD") is an under-diagnosed
genetic disease affecting an estimated 100,000 patients in the US.
It is characterized by insufficient levels of AAT causing
emphysema, loss of lung function, and decreased life expectancy.
Based on biochemical efficacy, plasma-derived AAT ("pdAAT") therapy
was approved in the 1980s and is administered weekly to maintain
serum AAT concentrations above 11 µM, which is below the normal
range. Since then, little progress has been made with new treatment
modalities and cost/supply of pdAAT remains a challenge.
The INBRX-101 study is an open-label, international Phase 1
trial designed to assess safety, pharmacokinetics ("PK"),
pharmacodynamics ("PD"), and immunogenicity (NCT03815396). AATD
patients were administered single or multiple doses (three
consecutive doses every three weeks) of 10, 40, 80 or 120 mg/kg
INBRX-101 via IV infusion.
As of November 2021, 24 AATD
patients have been administered INBRX-101 at doses of 10 mg/kg
(n=6), 40 mg/kg (n=6), 80 mg/kg (n=6) and 120 mg/kg (n=6).
INBRX-101 has been well tolerated without serious adverse
reactions, dose-limiting toxicities, or severe treatment emergent
adverse events. The most common drug related adverse events
reported were fatigue (n=5), pruritus (n=5), blood pressure
increased (n=5), urticaria (n=4), and infusion related reactions
(n=2). Infusion related reactions (e.g., pruritus, blood pressure
increased, urticaria, infusion related reactions) were transient,
mostly mild (Grade 1 per CTCAEv5.0) except for one moderate event
(Grade 2) and responded well to symptomatic therapy.
Serum antigenic PK and functional AAT levels were assessed in 21
AATD patients. Dose-related increases in maximal and total
INBRX-101 exposure were observed across the dose range of 10 to 120
mg/kg. A terminal half-life of approximately 15 - 19 days was
observed. Preliminary data from multiple doses of 40 mg/kg or 80
mg/kg every three weeks showed accumulation in line with the
prolonged half-life. Observed trough levels of functional AAT
exceeded those reported historically for pdAAT.
About Inhibrx, Inc.
Inhibrx is a clinical-stage
biotechnology company focused on developing a broad pipeline of
novel biologic therapeutic candidates in oncology and orphan
diseases. Inhibrx utilizes diverse methods of protein engineering
to address the specific requirements of complex target and disease
biology, including its proprietary sdAb platform. Inhibrx has
collaborations with 2seventy bio (formerly bluebird bio),
Bristol-Myers Squibb and Chiesi. For more information, please visit
www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-to-present-inbrx-101-data-at-ats-2022-annual-meeting-301518363.html
SOURCE Inhibrx Inc.